Molecular and clinicopathologic features of gliomas harboring NTRK fusions
Molecular and clinicopathologic features of gliomas harboring NTRK fusions
About this item
Full title
Author / Creator
Torre, Matthew , Vasudevaraja, Varshini , Serrano, Jonathan , DeLorenzo, Michael , Malinowski, Seth , Blandin, Anne-Florence , Pages, Melanie , Ligon, Azra H. , Dong, Fei , Meredith, David M. , Nasrallah, MacLean P. , Horbinski, Craig , Dahiya, Sonika , Ligon, Keith L. , Santi, Mariarita , Ramkissoon, Shakti H. , Filbin, Mariella G. , Snuderl, Matija and Alexandrescu, Sanda
Publisher
England: BioMed Central
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central
Subjects
More information
Scope and Contents
Contents
Fusions involving neurotrophic tyrosine receptor kinase (
NTRK
) genes are detected in ≤2% of gliomas and can promote gliomagenesis. The remarkable therapeutic efficacy of TRK inhibitors, which are among the first Food and Drug Administration-approved targeted therapies for
NTRK
-fused gliomas, has generated significant clinical interes...
Alternative Titles
Full title
Molecular and clinicopathologic features of gliomas harboring NTRK fusions
Authors, Artists and Contributors
Author / Creator
Vasudevaraja, Varshini
Serrano, Jonathan
DeLorenzo, Michael
Malinowski, Seth
Blandin, Anne-Florence
Pages, Melanie
Ligon, Azra H.
Dong, Fei
Meredith, David M.
Nasrallah, MacLean P.
Horbinski, Craig
Dahiya, Sonika
Ligon, Keith L.
Santi, Mariarita
Ramkissoon, Shakti H.
Filbin, Mariella G.
Snuderl, Matija
Alexandrescu, Sanda
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_a13bf05804df41039d210cc899efdb56
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_a13bf05804df41039d210cc899efdb56
Other Identifiers
ISSN
2051-5960
E-ISSN
2051-5960
DOI
10.1186/s40478-020-00980-z
